Artgen Biotech invests in RBT platform

Artgen Biotech Group is investing in the development of a platform for creating new subunit vaccines based on surface recombinant proteins and spherical adjuvant particles. Developer of the technology platform is RBT, a company within the Artgen Biotech group. Total investment in the development of the production component of the platform by RBT, including funds from private investors and debt financing, will amount to more than ₽80 million, of which ₽30 million in equity.